Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study

NCT05252598 is registered in ClinicalTrials.gov with Optimi Health Corporation as lead sponsor.

NCT NCT05252598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study
Lead sponsor
Optimi Health Corporation
Phase
Phase 1
Overall status
Withdrawn
Start date
January 31, 2023
Completion date
December 31, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, drug effect, health, subjective, mood change, mood disturbance, psilocin toxicity, psilocybin causing adverse effects in therapeutic use, psilocybin toxicity, psychedelic experiences, sleep disturbance